Ratings by Rodman & Renshaw (Seema Sheoran)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/24/2026 | Quince Therapeutics Inc. | QNCX | New Coverage | Buy (N/A) |
30.15 (31.73) |
5.24% | Details | |
| 7/21/2026 | Eledon Pharamceuticals | ELDN | New Coverage | Buy (N/A) |
3.86 (2.30) |
-40.41% | Details | |
| 6/3/2026 | Neurogene | NGNE | New Coverage | Buy (N/A) |
26.14 (23.55) |
-9.91% | Details | |
| 4/14/2026 | CAMP4 Therapeutics Corp | CAMP | New Coverage | Buy (N/A) |
4.64 (3.30) |
-28.88% | Details | |
| 4/2/2026 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
3.87 (2.84) |
-26.61% | Details | |
| 3/26/2026 | Enanta Pharmaceuticals | ENTA | New Coverage | Buy (N/A) |
12.17 (11.64) |
-4.35% | Details | |
| 3/26/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Buy (N/A) |
4.62 (9.58) |
107.36% | Details |
